Connect with us


Study shows lack of drug-susceptibility data for TB patients may increase resistance



Last Updated on April 19, 2024 by Robert C. Hoopes

A recent study conducted by HaystackAnalytics in collaboration with Dr. D.Y. Patil Medical College has shed light on the concerning issue of drug-resistant tuberculosis (TB) in India. The study, which analyzed real-world data from 600 clinical samples of TB patients, revealed some alarming findings.

According to the study, whole genome sequencing showed that pre-extensively drug-resistant TB (pre-XDR-TB) was present in 50.83% of cases, while multi-drug-resistant TB (MDR-TB) was found in 15.5% of cases. Interestingly, nearly equal proportions of pre-XDR-TB and MDR-TB were found among both men and women.

In cases where clinicians sent samples for sequencing in difficult-to-treat scenarios, relapse, and treatment failure situations, the study highlighted resistance to key drugs including rifampicin, isoniazid, and fluoroquinolones. XDR-TB, a rare type of MDR-TB resistant to isoniazid, rifampicin, fluoroquinolones, and second-line drugs, was also identified in some cases.

TB remains the second leading infectious disease globally, with over 1.35 lakh multi-drug-resistant cases reported in India in 2020. The CEO of HaystackAnalytics emphasized the need to rethink the approach to TB management in order to effectively address drug-resistant strains.

This study underscores the urgent need for continued research and innovation in the field of TB treatment and management. With the rise of drug-resistant strains, it is crucial for healthcare professionals and policymakers to work together to combat this growing threat and protect public health in India and beyond.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *